GSK Exploring Tykerb Potential In Patients Not Previously Treated With Herceptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Subset of breast cancer patients given lapatinib plus paclitaxel first line shows significant advantage in progression-free survival, duration of response.
You may also be interested in...
FDA Calls GlaxoSmithKline Professional Mailers For Tykerb “Misleading”
GSK shares FDA’s concerns, but says the promos were accompanied by full prescribing information, firm tells “The Pink Sheet” DAILY.
FDA Calls GlaxoSmithKline Professional Mailers For Tykerb “Misleading”
GSK shares FDA’s concerns, but says the promos were accompanied by full prescribing information, firm tells “The Pink Sheet” DAILY.
GSK Tykerb Opportunities Exist In Early Breast Cancer Setting – Oncologist
As many as 10 percent of early-stage HER2 positive breast cancer patients, who are not ideal candidates for Herceptin, could be candidates for Tykerb, oncologist Ellis estimates.